Metraipolis › archive › dc_cfb3fce11097
Neoadjuvant combined immunotherapy with intratumoral TransCon TLR7/8 Agonist and systemic TransCon IL-2 β/y or pembrolizumab in patients with locally advanced… — Europe PMC PMID:42709195
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/42709195
- DOI
- 10.1007/s00262-[numero omesso]-8
- License (as archived)
- solo-consultazione
- Archived
- 2026-10-16T04:24:20.056Z
- SHA-256 of the archived text
2c9a3d9fb7c3c0dc92308bb3ff68b3cd6310ad936781df9cf440adad79c238c3- Stable URL of this page
https://metraipolis.com/documento/dc_cfb3fce11097
How to cite
Neoadjuvant combined immunotherapy with intratumoral TransCon TLR7/8 Agonist and systemic TransCon IL-2 β/y or pembrolizumab in patients with locally advanced… — Europe PMC PMID:42709195 — Europe PMC (en), https://europepmc.org/article/MED/42709195 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_cfb3fce11097 (Metraipolis archive dc_cfb3fce11097, sha256 2c9a3d9fb7c3c0dc92308bb3ff68b3cd6310ad936781df9cf440adad79c238c3)
BibTeX
@misc{dccfb3fce11097,
title = {Neoadjuvant combined immunotherapy with intratumoral TransCon TLR7/8 Agonist and systemic TransCon IL-2 β/y or pembrolizumab in patients with locally advanced… — Europe PMC PMID:42709195},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/42709195},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_cfb3fce11097; sha256 2c9a3d9fb7c3c0dc92308bb3ff68b3cd6310ad936781df9cf440adad79c238c3},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42709195. Agents can read the archived copy with the MCP tool read_document.